193 related articles for article (PubMed ID: 29547583)
1. Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment.
Futakuchi M; Nitanda T; Ando S; Matsumoto H; Yoshimoto E; Fukamachi K; Suzui M
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29547583
[TBL] [Abstract][Full Text] [Related]
2. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
5. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.
Sadanandam A; Futakuchi M; Lyssiotis CA; Gibb WJ; Singh RK
BMC Cancer; 2011 Jul; 11():304. PubMed ID: 21774828
[TBL] [Abstract][Full Text] [Related]
6. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
7. The Effects of TGF-β Signaling on Cancer Cells and Cancer Stem Cells in the Bone Microenvironment.
Futakuchi M; Lami K; Tachibana Y; Yamamoto Y; Furukawa M; Fukuoka J
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31619018
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis.
Nannuru KC; Futakuchi M; Sadanandam A; Wilson TJ; Varney ML; Myers KJ; Li X; Marcusson EG; Singh RK
Clin Exp Metastasis; 2009; 26(7):797-808. PubMed ID: 19590968
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
10. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo.
Cicek M; Iwaniec UT; Goblirsch MJ; Vrabel A; Ruan M; Clohisy DR; Turner RR; Oursler MJ
Cancer Res; 2007 Nov; 67(21):10106-11. PubMed ID: 17974950
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
Futakuchi M; Nannuru KC; Varney ML; Sadanandam A; Nakao K; Asai K; Shirai T; Sato SY; Singh RK
Cancer Sci; 2009 Jan; 100(1):71-81. PubMed ID: 19038005
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.
Canon J; Bryant R; Roudier M; Osgood T; Jones J; Miller R; Coxon A; Radinsky R; Dougall WC
Bone; 2010 Jun; 46(6):1613-9. PubMed ID: 20215062
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
14. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
15. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
[TBL] [Abstract][Full Text] [Related]
16. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
17. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
20. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
